Here we report the most comprehensive exploration of genetic loci influencing human metabolism thus far, comprising 7,824 adult individuals from 2 European population studies. We report genome-wide significant associations at 145 metabolic loci and their biochemical connectivity with more than 400 metabolites in human blood. We extensively characterize the resulting in vivo blueprint of metabolism in human blood by integrating it with information on gene expression, heritability and overlap with known loci for complex disorders, inborn errors of metabolism and pharmacological targets. We further developed a database and web-based resources for data mining and results visualization. Our findings provide new insights into the role of inherited variation in blood metabolic diversity and identify potential new opportunities for drug development and for understanding disease.
The discovery of mutations causing severe congenital metabolic dis orders, or inborn errors of metabolism, revolutionized early under standing of how genes control biochemical reactions and metabolic pathways in the human body 1 . Recent technological advances in metabolomics and genetics allowing the collection of highdimensional data sets in large population samples suggest that inborn errors of metabolism are only extreme cases of a wide spectrum of genetic vari ation in human metabolism and that the loci involved often influence multifactorial traits and complex diseases. The socalled genetically influenced metabotypes (GIMs) identified thus far have been shown to display larger effect sizes than most loci associated with complex traits 2 and to map preferentially in or near genes that encode enzymes, metabolite transporters and regulators of metabolism [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] .
Although the biomedical and pharmaceutical relevance of these asso ciations may become clearer as focused genebygene investigations are conducted, little is known about their systemwide interconnectivity or how this knowledge can be translated into medical practice. A comprehensive blueprint of human metabolic pathways and the genes that regulate them would inform strategies for modifying deregulated metabolites in a rational and targeted manner, potentially using already existing drugs, as has been suggested for other genomewide association study (GWAS) findings 13 . In this context, genetic associations provide powerful tools to identify genes that could be targeted to modulate metabolite levels.
Here we present the most comprehensive investigation of genetic influences on human metabolism thus far, extending previous studies based on the same metabolomic platform 11, 14 . We applied powerful hypothesisgenerating genomewide scans to survey regions of the genome associated with a wide range of metabolic traits. The hun dreds of associations and their metabolic context reported in this A r t i c l e S study identify a systemwide atlas of molecular readouts of activity for human genes measured in vivo. We not only provide informa tion on hundreds of single genotypemetabolite associations, greatly expanding knowledge of metabolic intermediates of gene function and disease, but we also generate a network that includes the major ity of metabolites reliably measurable in blood using the Metabolon platform, allowing future exploration of perturbations caused by indi vidual genetic variants across hundreds of metabolites at once. This information is based on experimental in vivo data from a human pop ulation study, thus complementing classical metabolic pathway maps that have been obtained as composites of single in vitro biochemistry experiments. The newly discovered loci will empower future clinical and pharmacological research in a number of key areas, spanning from a better understanding of genetic predisposition to disease to the identification of potential new biomarkers, drug surveillance tools and drug targets and the causal evaluation of environmental and modifiable influences on human traits and disease 15 . Moreover, to maximize the downstream usefulness of the data for the broader scientific community, we have made the atlas freely available through an extensive suite of web resources, including a database of detailed functional annotations and disease associations for each locus and a network view of the data with links to genetic and metabolic web resources (see URLs). Below we summarize the key results of our study.
RESULTS

Eighty-four newly discovered metabolic loci
The study sample included a total of 529 metabolites profiled using liquidphase chromatography and gas chromatography separa tion coupled with tandem mass spectrometry in either plasma or serum from 7,824 adult individuals from 2 European population studies ( Supplementary Table 1 ). The entire KORA (Kooperative Gesundheitsforschung in der Region Augsburg) data set (n = 1,768) and a small proportion of the TwinsUK data set (1,052 individuals and 250 metabolites) have been described in 2 previous studies 11, 14 , with 5,002 TwinsUK individuals newly profiled in this study. Over half of the 529 metabolites (n = 333; 63%) were chemically identified and could be assigned to 8 broad metabolic groups (amino acids, carbohydrates, cofactors and vitamins, energy, lipids, nucleotides, peptides and xenobiotic metabolism) as described in the KEGG (Kyoto Encyclopedia of Genes and Genomes) database 16 . These groups could be further subdivided into 63 distinct biochemical path ways. Another 196 metabolites (37%) were classified as 'unknown' , indicating that their chemical identity was not yet determined at the time of analysis. Further information on the unknown metabolites, including measurement platform, retention time, m/z masstocharge ratio and fragmentation spectra, can be found in Supplementary  Table 2 . Analyte overlap between unknown and known metabolites was excluded using correlation analysis ( Supplementary Table 3 ). After stringent quality controls, a subset of 486 metabolites was avail able for genetic analysis in both cohorts, including 309 known and 177 unknown metabolites.
Primary genomewide discovery analysis was carried out on approximately 2.1 million SNPs, either directly genotyped or imputed from the HapMap 2 panel 17 and passing stringent quality control met rics (Online Methods and Supplementary Fig. 1 ). In this initial dis covery effort, 137 independent variants were significantly associated with metabolite concentrations at a stringent genomewide Pvalue cutoff of 1.03 × 10 −10 (= 5 × 10 −8 /486 metabolites; Supplementary Tables 4 and 5) 18 . Subsequent discovery analysis on 98,346 pairwise metabolite ratios identified 8 additional loci at a more stringent cutoff of 5.08 × 10 −13 (= 5 × 10 −8 /98,346 ratios; see the Supplementary Note for discussion on the interpretation of ratios). Overall, our study identified 299 SNPmetabolite associations of genomewide signifi cance at 145 statistically independent SNPs ( Fig. 1, Supplementary  Fig. 2 and Supplementary Table 5 ). Of these, 84 loci have not been reported before, and 3 loci were reported while this work was in revi sion 19 . Another 61 loci were identified in previous studies, suggesting validation across different platforms 2, 10, 11, 14, 20 . A subset of the loci was previously reported in smallerscale studies conducted in other tissues, suggesting that metabolite associations are reproducible across tissue types and that blood metabolite loci may for the most part be representative of associations in other tissues. For instance, all 5 genomewide significant loci detected in a study of urine in a discovery sample of 862 individuals 21 were also detected in blood in this study. In another example, the PYROXD2 locus was previously reported to be associated with a metabolite in urine detected by 1 H nuclear magnetic resonance spectroscopy 22 . The newly discovered loci identify a rich catalog of metabolic associations, allowing linkage of genetic and disease associations with underlying molecular mecha nisms and greatly enriching understanding of the genetic control of human metabolism. We systematically evaluated evidence for the genes within 1Mb windows centered on the sentinel SNPs to identify cases where the function of the gene matched the relevant metabolite (Online Methods). This effort identified a plausible or established biochemical link for 101 of the 145 loci, involving 94 unique genes (reviewed in Supplementary Table 6 ). We henceforth refer to these 94 genes as 'predicted causal' . For the remaining loci, we annotated the gene nearest to the association peak.
Where a predicted causal gene was associated with a metabolite ratio and both metabolites had been identified, we could character ize the ratio in terms of the underlying biochemistry. In 11 cases, the metabolite ratio seemed to reflect flux through a particular metabolic reaction that was influenced by the SNP (annotated as 'activity' in Supplementary Table 6 ). For instance, a variant in GOT2 (encoding mitochondrial glutamicoxaloacetic transaminase 2) was associated with the ratio between phenyllactate and phenylalanine. GOT2 cata lyzes the conversion of phenylalanine to phenylpyruvate, which is then converted into phenyllactate 23 . Another such example was MBOAT7, associated with the ratio of arachidonate (20:4n6) to 1arachidonoylg lycerophosphoinositol. MBOAT7 encodes a lysophosphatidylinositol acyltransferase that has specificity for arachidonoylCoA as an acyl donor 24 . Arachidonate is readily converted to arachidonoylCoA.
In five cases, either both metabolites in a ratio were linked to a sub strate or both were linked to a product (for instance at ACE, SULT2A1, AKR1C4, ABP1 and THEM4). In these cases, the effect of the genetic variant may be explained as causing one molecule to be consumed or acted on faster than the other ('selectivity').
In seven cases, the levels of one metabolite 'normalizing' the statis tical signal for the other may explain the association with the ratio. For instance, PRODH encodes proline dehydrogenase, which catalyzes the first step in proline degradation 25 . However, the P value for the ratio of valine to proline was even stronger than the P value for proline itself, suggesting that valine may be normalizing the proline concentration against the overall amino acid pool.
A de novo atlas of human metabolic relationships in blood
We next generated a network view of geneticmetabolic interactions in the two cohorts by combining genetic and metabolite infor mation. First, we connected metabolites with metabolites using Gaussian graphical models (GGMs), which are based on partial cor relation coefficients. We have previously shown that GGMs connect npg biochemically related metabolites 14, 26 and can be applied to reconstruct metabolic pathways directly from metabolomics data. Second, we connected metabolites with genetic loci on the basis of our primary GWAS results, with one link for each genomewide significant association. For a more detailed description of the network generation process, see the Supplementary Note. To verify the stability of partial correlation values in both cohorts, we performed a bootstrappingbased subsam pling approach. We observed generally low standard deviation, especially for high partial correlation values, indicating high stability for the estimation. The resulting network (Fig. 2) recapitulates the relationships between 397 metabolites from 60 different pathways (249 known and 148 unknown) and 131 of the 145 genetic loci. To our knowledge, it provides the first comprehensive and highresolution ref erence map of human metabolic relationships and their genetic influences measured in a single in vivo 'experiment' in blood.
This in vivo reference map complements existing knowledge of genemetabolite relationships in specialized biochemical databases. It facilitates the visualization of genetic associations in the context of complex relationships between metabolites and SNPs, as illustrated by the subnetwork of dipeptide and oligopeptide metabolites and peptiderelated genes ( Fig. 2, box) . To maximize the usefulness of the data for the scientific community, we have made the network available for download with extensive biochemical and biological annotations (see URLs). We have further made available a version of the network with basic annotation through a web browser, allowing rapid visualization and exploration of the data. Furthermore, an extensive database of genetic associations and their biological, medical and pharmacological annotations is avail able in Supplementary Table 6 and through the supporting online website (see URLs).
Allelic architecture of metabolic loci
To fully quantify the extent to which metabolic loci capture variance in metabolite concentrations, we carried out exhaustive characteriza tion of the allelic architecture of the newly discovered loci. Metabolite heritabilities were estimated using the classical twin (ACE) model and the twin structure of the TwinsUK cohort ( Fig. 3 and Supplementary Note). The contribution of metabolic loci to variance in metabolite con centrations was high (median of 6.9%, range of 1-62%; Supplementary   Table 7 and Supplementary Note), with variants explaining greater than 20% of heritability for approximately 10% of the metabolites and greater than 50% of the heritability in four cases. These findings sup port previous observations that variants explain on average greater proportions of trait variance for some metabolite classes than what is generally observed for complex traits 2 , confirming the value of these intermediate molecular traits for dissecting genetic contributions to complex traits with greater statistical power. We carried out local imputation with a denser haplotype reference map (1000 Genomes Project) for each of the 145 loci to explore the contribution of addi tional variants with lower minor allele frequency present in this panel and poorly represented by HapMap 2 imputation. With the exception of the CYP3A cluster, the two imputation panels yielded lead SNPs with highly correlated frequencies, P values and explained variance at most loci ( Supplementary Fig. 3 and Supplementary Table 8 ).
We further explored the contribution of SNPSNP interactions between the metabolic loci, defined as a departure from additive marginal effects (Online Methods). This analysis suggested that the effects of metabolic loci were predominantly additive, apart from the statistically significant interaction observed between NAT8 and PYROXD2 vari ants 22 (Fig. 4, Supplementary Fig. 4 and Supplementary Table 9 ). 22 
npg
A r t i c l e S Finally, we systematically compared the metaboliteassociated SNPs against public repositories of variants (cis expression quantita tive trait loci, ciseQTLs) affecting gene expression in liver 27 , fat, skin and lymphoblastoid cell lines (LCLs) 28 . For each lead metabolomic SNP, we first retrieved all SNPs with high linkage disequilibrium (r 2 ≥ 0.8) in the 1000 Genomes Project pilot phase (CEU population of European ancestry). Each lead SNP and its proxies were then used as baits to search for ciseQTL SNPs in these four tissues. A total of 57 lead SNPs identified ciseQTLs in at least 1 of the 4 tissues searched under a nominal permutation P value of <0.001, defining a total of 101 SNPgene pairs and 97 different genes ( Supplementary Table 10 ). Of the 97 genes, 38 were predicted to be causal on the basis of our annota tion and 59 were predicted to be noncausal. When compared to non causal genes, causal genes showed 3.25fold enrichment in the liver eQTL data set (Fisher's exact test P value = 0.023, twotailed), pos sibly reflecting the greater contribution that liver metabolism makes to blood metabolite levels. Furthermore, causal genes were enriched by 1.6fold in fat compared to noncausal genes (Fisher's exact test P value = 0.038, twotailed). No enrichment was seen in LCLs or skin.
One major challenge in interpreting associations from GWAS is formulating and testing hypotheses on the causal effects of a SNP on an associated trait. We argued earlier that molecular QTL studies on metabolite concentrations or gene expression have greater statistical power than with more complex traits such as, for instance, high density lipoprotein (HDL) or lowdensity lipoprotein (LDL) choles terol levels 2 . In this context, the parallel analysis of SNPs, metabolite concentrations and other molecular phenotypes (for instance, epige netic profiles or transcript levels) provides new opportunities to inves tigate causal pathways at the molecular level (Supplementary Note). We applied mendelian randomization analysis to test the hypothesis that metaboliteassociated SNPs affect metabolite concentrations through variation in the transcript levels of corresponding causal genes. We focused on a subset of 32 predicted causal genes that had a matching eQTL in at least one MuTHER (Multiple Tissue Human Expression Resource) tissue and used a subset of 484 individuals from the MuTHER data set for whom gene expression levels were measured at the time of metabolomic measurement (Online Methods). This analysis identified two loci that were significant at the Bonferroni corrected P value of <1.5 × 10 −3 , namely THEM4 and CYP3A5. In both cases, the allele associated with increased metabolite levels was associated with decreased gene expression in one or more tissues ( Fig. 4 and Supplementary Table 11 ). This analysis provides support for the notion of underlying causal variants having regulatory consequences for these two loci. 
Genetic association Metabolic association
Unknown Association between metabolite ratio and locus 2 Lysolipid (23) 8 Fatty acid-short chain (1) 9 Fatty acid-dicarboxylate (5) 10 Fatty acid-essential (7) 11 Fatty acid-other (3) 13 Carnitine (14) 18 Inositol (2) 20 Food component or plant (5) 25 Purine-xanthine or inosine (4) 26 Purine-guanine (2) 27 Pyrimidine-uracil (2) 28 NAD metabolism (1) 29 Krebs cycle (4) 30 Oxidative phosphorylation (2) 31 Fructose, mannose and galactose (4) 32 Glycolysis and gluconeogenesis (5) 33 Aminosugar (1) 34 Creatine (2) 35 Glycine, serine and threonine (6) 36 Lysine (3) 38 Alanine and aspartate (4) 39 Histidine (2) 40 Cysteine, methionine, SAM and taurine (4) 43 Phenylalanine and tyrosine (10) 46 Urea cycle, arginine and proline (8) 51 γ-glutamyl (5) 50 Polypeptide (2) 54 Ascorbate and aldarate (3) 57 Vitamin B 6 (1) 58 Pantothenate and CoA (1) 56 Hemoglobin and porphyrin (5) 55 Tocopherol (2) 53 Fibrinogen cleavage peptide (3) 52 Dipeptide (9) 49 Polyamine metabolism (1) 48 Amino fatty acid (1) 47 Guanidino and acetamido (1) 45 Tryptophan (10) 44 Glutathione (2) 42 Branched-chain amino acid (14) 41 Butanoate (3) 37 Glutamate (3) 24 Purine-urate (2) 23 Purine-adenine (1) 22 Xanthine (5) 21 Sugar or starch (1) 19 Benzoate (5) 17 Sphingolipid (1) 16 Sterol or steroid (14) 15 Bile acid (6) 14 Ketone body (1) 12 Eicosanoid (1) 7 Fatty acid-medium chain (9) 6 Fatty acid-long chain (17) 5 Fatty acid-branched chain (1) 4 Fatty acid-amide (1) 3 Glycerolipid (4 Figure 2 A network view of genetic and metabolic associations. The network view was built by combining genetic associations with a GGM network created from metabolite concentrations. Each node represents either a set of metabolites belonging to the same pathway (circular nodes) or a genetic locus (diamond-shaped nodes). An edge between a pathway and a locus was drawn if at least one metabolite showed a genome-wide significant association with the locus. A line between two pathway nodes was drawn if there was at least one connection in the underlying metabolite GGM network between two metabolites in the respective pathways (Online Methods). Nodes are colored as in Figure 1 . Numbers within metabolite loci indicate pathway names as detailed to the left. Numbers associated with each pathway name indicate the number of metabolites contained within each pathway node. Box, example of a network with full-detail resolution. The network is provided in digital form for interactive viewing at the supporting online website (see URLs). The fully annotated network is also available for download in Cytoscape format from the same website.
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A r t i c l e S
Biological relevance
The newly discovered associations span the large majority of the met abolic pathways explored, indicating widespread genetic influences on the human metabolome. We could assign a known biochemical function to approximately twothirds of the overall associations (101 of the 145 loci; Supplementary Table 6 ). Onethird (n = 34) of the newly discovered loci involved amino acids, and a similar number (n = 33) were involved with intermediates of lipid metabolism, includ ing sterols, carnitines and intermediates of inositol and fatty acid metabolism. The remaining newly discovered associations were across a wide range of metabolic classes and functions, notably pathways with a central role in cellular metabolism and energy, intermediates of purine and pyrimidine metabolism, glucose homeostasis, and vitamin and cofactor levels, among others. In cases where a metabolite was of unknown identity, the metabolic function of the associated gene provided a hypothesis on its identity, as described previously 14 .
The current characterization of hundreds of loci embedded in their metabolic context further allows exploration of complex systems to a greater depth and breadth than in previous studies 2, 10, 11, 14, 20 . For instance, 12 newly discovered associations were within phenylalanine, tyrosine and tryptophan metabolism pathways, implicated in key brain functions through dopamine and serotonin biosynthesis. Among these associations, two common variants in TDO2 (encoding tryptophan 2,3dioxygenase) and IDO1 (encoding indoleamine 2,3dioxygenase 1) were associated with the concentrations of tryptophan and 4hydroxytryptophan (X12100), respectively, two intermediates in the C -g ly c o s y lt ry p to p h a n C -g ly c o s y lt ry p to p h a n K y n u re n in e K y n u re n in e T ry p to p h a n b e ta in e T ry p to p h a n b e ta in e T ry p to p h a n T ry p to p h a n S e ro to n in ( Figure 3 Heritability and variance explained. We used the ACE model to partition the variance for each metabolite into narrow-sense heritability and common and unique environmental components. The proportion of heritability explained by all SNPs associated with a given metabolite at the genome-wide level is shown in red. The corresponding numeric values for heritability estimates are given in Supplementary table 7. npg A r t i c l e S synthesis of the neurotransmitter serotonin. Several loci mapped to transporters, including association of plasma tyrosine and tryptophan levels with SLC16A10 (encoding the Ttype amino acid transporter 1 (TAT1) for tryptophan, tyrosine and phenylalanine 29 ), associations of plasma kynurenine levels with SLC7A5 (encoding LAT1), which medi ates cellular exchange of tryptophan and the tryptophan metabolite kynurenine 30 , and many others. It will be important to characterize whether these associations provide reliable molecular readouts of the function of these genes in the brain to ascertain the value of accessible tissues such as blood for dissecting genetic influences on systems that are not readily accessible in vivo. As shown with this example, all asso ciations in this study can now be used in a similar manner to explore other diseaserelevant connections. Finally, we note that metabolomics analysis in blood reflects a cumulative readout of processes that occur in different metabolically active tissues, including the uptake, release, production and disposal of biochemicals from individual organs. Thus, whether any of the genetic variants that we report here has an effect in a specific tissue will depend on whether the respective protein is actually expressed and active in that tissue. It is possible and even likely that analyses in individual tissues will show even more distinct metabolic profiles and stronger genetic associations than those observed here. A greater characterization of patterns of tissue specificity for metabo lite levels and associations will be necessary to address this question.
Disease and pharmacological relevance
Integration of metabolic associations with complex traits and disease empowers understanding of the molecular underpinnings of disease, as shown in the case of the bradykininkininogenkinin system and cardiovascular disease ( Supplementary Fig. 5 and Supplementary Note). We searched the National Human Genome Research Institute (NHGRI) GWAS Catalog (July 2013) for cases where the sentinel SNP either matched a variant associated with a complex trait or disease or was in high linkage disequilibrium with one (defined as r 2 ≥ 0.8; Online Methods). A total of 41 metaboliteassociated SNPs (Supplementary Table 4 ) and 14 of 84 newly discovered SNPs matched SNPs previously associated with complex disease or drug response endpoints ( Fig. 5 and Supplementary Table 4 ). We fur ther searched the 1Mb intervals centered on the associated SNPs for Figure 4 Epistatic effects and mendelian randomization analyses on eQTL loci. (a) Interaction between NAT8 and PYROXD2 variants. Box plots display the levels of the metabolite X-12093 in individuals grouped by their genotypes at the two variants rs10469966 (NAT8) and rs4488133 (PYROXD2) ( Supplementary  Fig. 4 ). (b) Regional plots showing overlap of association of SNPs with metabolite and gene expression levels.
Association P values (−log 10 scale) are plotted for a 1-Mb window surrounding the lead SNP rs6693388 and for associations of the SNP with the ratio of linoleate (18:2n6) to 5,8-tetradecadienoate (red) and with THEM4 expression in fat (black), skin (blue) and LCLs (green). (c) Example of the relationships tested by mendelian randomization analysis at the same locus, where expression of THEM4 is shown to mediate the association between rs6693388 and the ratio of linoleate (18:2n6) to 5,8-tetradecadienoate. All analyses were carried out in a subset of 484 unrelated TwinsUK participants with gene expression information obtained at the same time as metabolomic measurement. Full results are in Supplementary table 11 . CI, confidence interval. Supplementary Table 12 ). As recently postulated 31 , this suggests that several genes (including CPS1, UGT1A1, CBS, SLC22A4SLC22A5 and others) harbor genetic variants with effects ranging from lossof function alleles in metabolic disorders all the way to common poly morphisms with moderate phenotypic consequences in multifactorial complex diseases and, finally, quantitative variation within the nor mal range of healthy individuals. One such example was the CPS1 locus, encoding a mitochondrial carbamoyl phosphate synthetase, an enzyme catalyzing the generation of carbamoyl phosphate from ammonia and bicarbonate. Rare mutations in CPS1 cause carbamoyl phosphate synthetase I deficiency, a severe autosomal recessive dis order characterized by congenital hyperammonemia and defective citrulline synthesis. A common variant in CPS1 was previously associ ated with increased risk of chronic kidney disease 32 . The same variant was associated with glycine levels in this and previous studies 10, 20, 33 . Glycine is interconverted to ammonia via the glycine cleavage com plex 34 and provides a molecular intermediate trait for detection of the disease.
The extension of clinical chemistry analysis to a richer set of metab olites in this study and the underlying linkage to genetic differences further present new opportunities to identify variants of possible pharmacogenomic relevance and new pharmacological targets. Of the 132 unique genes associated with the 145 metabolic loci, 56 (42%) identified genes of potential interest for pharmacological develop ment. Of these, 24 (18%) included drug targets (10 genes), drug metabolizing enzymes (11 genes) or transporters (3 genes) for US Food and Drug Administration (FDA) and/or European Medicine Agency (EMA)approved drugs. For instance, 45 different FDA approved drugs with a broad range of indications were linked with the 10 drug targets alone (Supplementary Table 13) . A further 11 genes encoded drug targets for compounds in early to late stages of development (from preclinical to phase I, II and III trials through registration), and 24 genes were linked to drugs that are either sus pended or discontinued or have no reported development activity ( Supplementary Table 14 ). Thus, overall, 21 of the 132 reported genes (16%) were either established or promising drug targets. This finding indicates that druggable targets are highly enriched within metabolomic loci (2.8fold enrichment, χ 2 test P value = 1.19 × 10 −5 ) compared to the estimated druggable fraction of human genes (1,089 of 19,258 human genes or 5.6%; ref. 14). Finally, 21 additional genes were targets, drugmetabolizing enzymes or transporters for bioactive druglike compounds ( Supplementary Table 6 ). In these and other cases, the metabolic associations and linkage to disease status identify possible new therapeutic targets concordant with biomarkers for the clear establishment of efficacy and may inform patient stratification based on genetic profiling. Furthermore, the associated metabolites identify potential biomarkers that are readily detectable in accessible samples, for example, urine or plasma, and that may improve the evaluation of disease or efficacy of new medicines while accounting for individual genetic background. Finally, this catalog of associa tions provides new opportunities for drug repositioning or for the identification of new indications for existing drugs, thus potentially unlocking some of the original investment.
DISCUSSION
In summary, we carried out the most comprehensive analysis of genetic influences on human blood metabolites thus far. Our observations suggest widespread genetic control over a large range of different pathways and functions and support the notion of human metabolism as a complex continuum governed by genetic effects of variable inten sity, complex regulatory influences and nongenetic effects. Our results advance knowledge in a number of areas of biomedical and pharmacogenetic interest, generating nearly 100 new hypotheses of SNPmetabolite and disease correlates and identifying a large catalog of new potential biomarkers as well as associations to drug targets, transporters and metabolic enzymes. Lastly, the network provides a comprehensive in vivo reference map of genetic influences on blood metabolites in a healthy human population sample, linking genetic variants to hundreds of biochemical relationships and pathways. The data and results generated by this study are made freely avail able through a webbased database and a downloadable network to facilitate the necessary functional and clinical exploration of these new hypotheses.
URLs.
A supporting online website summarizing genetic asso ciations and biological and disease annotations from this study and providing a searchable version of the metabolic network is accessible at http://gwas.eu/si. A fully annotated version of the network in Cytoscape format is available for download at http://metabolomics.helmholtzmuenchen.de/gwa/si/network/SI_ network.cys. Genomewide association statistics are freely accessi ble through the Metabolomics GWAS Server at http://metabolomics. helmholtzmuenchen.de/gwas/. Gene expression data are available at http://www.muther.ac.uk/. Raw metabolomic measurements can be accessed, together with genomewide genotype data, through applica tion to the respective data access committees, available at http://epi. gsf.de/koragen/seiten/angebot_regel_e.php?page=Services (KORA) and http://www.twinsuk.ac.uk/dataaccess/ (TwinsUK). Orphanet, a list of all 501 genes contributing to an inborn error of metabolism, can be found at http://www.orpha.net/consor/cgibin/Disease_Classif. php?lng=EN&data_id=150&PatId=10507&search=Disease_Classif_ Simple&new=1. The Citeline Pharmaprojects Pipeline can be found at http://www.citeline.com/products/pharmaprojects/.
METHODS
Methods and any associated references are available in the online version of the paper.
Note: Any Supplementary Information and Source Data files are available in the online version of the paper.
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ONLINE METHODS
Study samples. The TwinsUK cohort is an adult UK twin registry composed of mostly women aged 18 to 102 years. These twins were recruited from the general UK population through national media campaigns and were shown to have similar diseaserelated and lifestyle characteristics to populationbased singletons in the same age group 35 . The samples used in this study were 93% female in the age range of 17 to 85 years (mean of 53 years). The Cooperative Health Research in the Region of Augsburg (KORA) study is a series of inde pendent populationbased epidemiological surveys and followup studies of participants living in the region of Augsburg in southern Germany 36 . The present study includes data from the followup study KORA F4 (2006) (2007) (2008) of the KORA S4 survey (1999/2000) . Individuals were aged between 32 and 77 years (mean of 61 years), and there were equal numbers of males and females (Supplementary Table 1 ). All participants in both TwinsUK and KORA have given written informed consent, and local ethics committees, the Guy's and St. Thomas' Hospital Ethics Committee for TwinsUK and Bayerische Landesärztekammer for KORA, approved the studies.
Primary genome-wide association analysis for metabolites. Primary asso ciation testing was carried out at each SNP (in the HapMap 2-based imputed genotype data set) for all 486 metabolite concentrations present in both the TwinsUK and KORA data sets after quality control steps. Linear regres sion models (assuming an additive genetic model) were used. Age and sex were included as covariates in both cohorts. Additionally, batch effect (see 'Metabolomics data acquisition and preprocessing' in the Supplementary Note) was added to the model only in TwinsUK, as the 1,768 KORA individu als were processed in a single batch. In TwinsUK, associations were carried out using Merlin software 37 . Briefly, Merlin is based on the variancecomponent regression model and provides two familybased association tests under mul tivariate normality assumptions: a likelihood ratio test and a score test. In con trast to recently developed linear mixed model-based programs that estimate individual relationships from genotypes, Merlin takes pedigree information from direct input of family pedigrees and reported twin status (monozygotic or dizygotic). Association tests were run on bestguess genotypes (where genotypes were called if they had a posterior probability of >0.9) using the computationally more efficient score test. In KORA, linear models were fit for unrelated individuals using QUICKTEST 38 software. Briefly, QUICKTEST is based on maximumlikelihood estimation and assesses association tests for unrelated individuals under a linear model framework with the assumption of a normal mixture model for error distribution. QUICKTEST can handle uncertain genotypes (for example, imputed genotypes with uncertain scores) and nonnormal traits (for example, traits with skewness and heavy tails). Association tests were carried out on allelic dosages (0-2), accounting for uncertainty in imputed genotypes. For the 145 most associated SNPmetabolite pairs, associations were recalculated in TwinsUK using allelic dosage to ensure that association results were not affected by genotype modeling. The resulting association P values were virtually identical to those obtained from Merlin (R 2 = 0.99), demonstrating that there was no bias associated with the use of bestguess genotypes in TwinsUK and allelic dosages in KORA.
Meta-analysis.
Association results in TwinsUK and KORA were combined using inverse variance metaanalysis based on effect size estimates and stand ard errors, adjusting for genomic control. Heterogeneity in each association between data sets was tested using Cochran's Q test (which is equivalent to the McNemar test here as the number of data sets is two). All above analyses were carried out using Metal software 39 . To control for false positive error rates resulting from the large number of SNPs tested, a conservative Bonferroni adjusted P value of 1.03 × 10 −10 (=5 × 10 −8 /486) was applied in declaring genomewide significance for the SNPmetabolite associations. SNPs with low imputation quality (info < 0.4), low minor allele frequency (<0.01) or significant heterogeneity of effects between the two cohorts (defined by het erogeneity P < 0.001 and a P value in either cohort of ≥0.001 = 0.05/486) and SNPs present in only one cohort were removed after metaanalysis. A lead SNP at each locus was selected as the SNP with the lowest P value for association with any trait at that locus. For each metabolite, all associations passing this cutoff were assigned to independent loci by iteratively allocating the lead SNP with the lowest P value and SNPs within 500 kb of it into the same locus. These assignments were further revised as described below to estimate the effective number of independent loci.
Genome-wide analysis of metabolite/metabolite ratios. A second dis covery step was carried out by testing genomewide associations on all 98,346 (=444 × 443/2) pairwise ratios of metabolite concentrations present in both cohorts after quality control steps, following the principle described pre viously 11 . Xenobiotic metabolites were excluded owing to the low average call rates per individual. Because of the large high of traits and computation time and costs, for metabolite ratios, genomewide analyses were carried out in the TwinsUK study alone, followed by replication of significant hits (Bonferroni corrected P < 5.08 × 10 −13 = 5 × 10 −8 /98,346) in KORA. SNPs with low minor allele frequency (<1%) and info (<0.4) were removed from analysis, as in the association analysis for single metabolites. In the analysis in TwinsUK, a total of 430 loci survived Bonferroni correction, and only the top association for each locus (the metabolite ratio and the SNP pair with the lowest P value) was carried forward for replication in KORA. Metaanalysis was performed on both discovery and replication results using the inverse variance model, and the com bined result was filtered again by Bonferroniadjusted P value < 5.08 × 10 −13 and heterogeneity P ≥ 0.001. Further details on the interpretation and report ing of ratios are provided in the Supplementary Note.
Refinement of independence at metabolite loci. A series of additional analyses
were carried out to further refine the identity of single metabolite-and metabolite ratio-associated loci. Regional association plots were visually inspected to identify possible independent signals within each locus or to detect possible signals spanning two consecutive loci. For loci where putative independent SNPs were identified (defined as two SNPs having r 2 ≤ 0.5 in the 1000 Genomes Project CEU population), conditional analyses were used to assess the statistical independence of the two loci. Specifically, we reciprocally tested association with each SNP while adding the second SNP as a term in the linear model. Bonferroni correction for the number of pairs tested was applied to declare significance for the conditional test P value. In the case of nonindependence, the best SNPmetabolite pair with the lowest association P value was reported at each locus.
Total heritability estimates. Genetic and environmental influences on the concentrations of 503 single metabolites present in TwinsUK after quality control steps were inferred under the ACE model (which models trait variance as a function of additive genetics, common environment and unique environ ment and/or error effects). Narrowsense heritabilities were inferred from the proportion of the total variance explained by estimated additive genetic effect. To estimate parameters of the ACE model, a maximumlikelihood method was applied under multivariate normality assumptions using OpenMx software 40 , adjusting for age, sex and batch effect ( Supplementary Table 7 ). Metabolites measured in fewer than 30 twin pairs (either monozygotic or dizygotic) were excluded from calculations for heritability estimation.
Known heritability estimates under additive models. Next, known her itability was estimated for 170 single metabolites associated with genetic variants in our GWAS. The explained genetic variance of each metabolite was estimated by multiple regression analysis including all associated SNPs under additive genetic models, after adjusting for covariates (age and sex in KORA; age, sex and experimental batch effect in TwinsUK). Only unrelated twin individuals were used for the analysis to avoid biases due to familial correlation. Known heritability was defined as the ratio of total variance in the metabolite to the variance explained by the multiple regression models including all SNPs significantly associated with the metabolite. This known heritability was then compared with the total heritability inferred above ( Supplementary Table 7 ). Imputation using denser haplotype maps from the 1000 Genomes Project. Genetic variants associated with metabolite concentrations below the genomewide significance cutoff might contain true signals contributing to metabolite heritability. To more comprehensively survey genetic variation at the 145 metabolic loci, associations at each locus were recalculated fol lowing imputation using a denser reference set (1000 Genomes Project) 41 .
npg Genomewide genotypes were imputed using the 1000 Genomes Project multipopulation panel (March 2012 release for TwinsUK; June 2011 release for KORA), and associations with metabolite concentrations were tested as described within a 1Mb window centered on each lead SNP. Analyses were carried out in TwinsUK and KORA separately, and the results were com bined by inverse variance metaanalysis, following the procedure used in the HapMap 2-based GWAS. Minor allele frequency, association P value and the variance explained by the two models (Y = α + β × SNP 1KGP + ε and Y = α + β × SNP HM2 + ε) were then compared for the most strongly associated SNPs identified in HapMap 2-and 1000 Genomes Project-based imputation (respectively, SNP HM2 and SNP 1KGP ). Finally, the explained genetic variance of each metabolite was estimated by multiple regression analysis including all associated SNP 1KGP markers under an additive genetic model and com pared with total heritability and with known heritability estimated by multiple regression analysis including all originally associated SNP HM2 markers under an additive genetic model. Overall, at 80% of the loci, 1000 Genomes Project-based imputation yielded a different variant than the HapMap 2 imputation used for discovery ( Supplementary Table 8 ). However, the 1000 Genomes Project-based lead SNPs had similar minor allele frequencies (R 2 = 0.85), association P values (R 2 = 0.99) and explained variance (R 2 = 0.96) to the HapMap 2-based SNPs (Supplementary Fig. 3a-c) , with only one locus (CYP3A4CYP3A5) showing a significant improvement in association in the 1000 Genomes Project data set ( Supplementary Fig. 3d,e ).
Epistatic interactions in known heritability estimates. Frequent statistical interaction (epistasis) between genetic variants has been proposed to inflate heritability estimates by creating socalled phantom heritability 42 . Although exhaustively testing interactions between SNPs across the genome for all traits would be statistically intractable, it is nevertheless of interest to explore possible epistatic effects between genomewide significant SNPs, particularly given their cooccurrence within tight metabolic networks. To test for epistasis, we focused on all pairs of SNPs associated with the same metabolite at genomewide sig nificance (106 pairs of SNPs associated with 51 metabolites; Supplementary  Table 9 ). SNPSNP interaction was defined as a departure from additive mar ginal effects and was verified by an ANOVA F test comparing the following two models with and without an interaction term, γ × SNP 1 × SNP 2 : The same covariates used in the primary discovery effort (age and sex in KORA; age, sex and batch effect in TwinsUK) were included in each model. For simplicity, in TwinsUK, only unrelated individuals were included in the analysis. A Bonferronicorrected P value of 0.00047 (= 0.05/106) was applied to declare significant epistasis. These tests identified no evidence for interac tion among the associated loci (P ≤ 4.7 × 10 −4 = 0.05/106), suggesting a lack of strong interaction effects among the loci tested. Exceptions included vari ants at two loci (rs10469966 in NAT8 and rs4488133 in PYROXD2) for which a significant interaction was observed on metabolite X12093 in TwinsUK (ANOVA Ftest P = 1.63 × 10 −5 ) and replicated in KORA (P = 5.71 × 10 −11 ; Fig. 4 and Supplementary Fig. 4) . Fitting the interaction model yielded a modest increase in explained trait variance compared to the additive model (R int 2 = 15.6% versus R add 2 = 14.4% in TwinsUK; R int 2 = 27.7% versus R add 2 = 24.2% in KORA).
Bioinformatics annotation of genes at metabolite-associated loci. The 1,968 proteincoding genes within 500 kb of any of the lead SNPs were systematically annotated to identify cases where gene function could be linked biochemically to the associated metabolite (predicted causal genes). First, each gene was annotated for its distance and linkage to lead SNPs. A graphbased method was used to find potential paths from each gene to linked metabolites, with edges derived from the data in KEGG 16 and EHMN (Edinburgh human metabolic network reconstruction) 43 . Comprehensive text mining was then used to iden tify all PubMed abstracts mentioning a synonym of the gene and a synonym of the linked metabolite(s). The assembled evidence was reviewed locus by locus. Possible causal genes at each locus were carefully reviewed in BRENDA 44 and in the primary literature, and the gene with the highest functional plausibility was selected on the basis of a preponderance of the evidence. Because of the rich literature in biochemistry and enzymology going back at least four dec ades, predicted causal genes could be identified for the vast majority of the loci with known metabolites. When a predicted causal gene was not identified, the locus was annotated with the gene nearest to the metaboliteassociated SNP.
Annotation of genes for inborn errors of metabolism. To annotate over lap with genes causative for inborn errors of metabolism, we retrieved from Orphanet (see URLs) a list of all 501 genes contributing to an inborn error of metabolism and compared this list to the list of all genes located within 500 kb of each of the 145 lead SNPs. Of the 501 genes, 26 were in our list of 94 predicted causal genes. Against a background of 19,297 proteincoding genes, this corresponds to highly significant enrichment (hypergeometric test P value = 5.9 × 10 −16 ). This is in fact the strongest P value for any 'branch' or subgroup within the Orphanet ontology.
Annotation of variants mapping to complex trait and disease loci.
To identify cases where metabolomicassociated SNPs had previous evidence of association with complex traits and disease, we first retrieved all variants from 1000 Genomes Project Pilot 1 data having high linkage disequilibrium with the 145 sentinel SNPs (defined by r 2 ≥ 0.8 in the CEU sample). These variants were then compared against the NHGRI GWAS Catalog (July 2013 release) with the search set to all available traits and diseases. These cases were anno tated in Supplementary Tables 4 and 6 in the field "Complex trait association [PMID]". Cases where the variant matched a metabolic trait association using the same rule were annotated in the "Metabolite association [PMID]" field, also in Supplementary Table 6 .
Annotation of variants mapping to expression QTLs.
A thorough analysis of eQTL signals at the lead SNPs was conducted as follows. For each lead metabolomic SNP, we first retrieved all SNPs with high linkage disequilibrium (r 2 ≥ 0.8) in the 1000 Genomes Project pilot phase (CEU population). Each lead SNP and its proxies were then used as baits to search the MuTHER Project expression database 28 and a published liver eQTL data set 27 . All significant cis eQTLs within a 1Mb window centered on the lead SNP were retrieved from these data sets, and the best eQTL P value in each tissue was noted. A total of 57 lead SNPs identified ciseQTLs in at least 1 of the 3 tissues searched under nominal or permutation P < 0.001 ( Supplementary Table 10 ). For additional information, see the Supplementary Note.
Mendelian randomization analysis on causal metabolite pathways. Relative normalized gene expression values for all eQTLs identified were retrieved for 484 unrelated TwinsUK participants with available genotype data and with gene expression and metabolite data obtained at the same time point by the MuTHER Project 28 in 3 tissues (fat, skin and LCLs). Mendelian randomization 45 analysis was used to test the hypothesis that changes in gene expression levels would cause changes in metabolite levels, using the genotype of the lead SNP as an instrumental variable. The causal effect of gene expression levels on metabolite levels was estimated by the Wald ratio method 15 is the coefficient for the linear regression model of gene expression levels on SNPs. Covariate adjustments (age, sex and batch effect for metabolite levels; age, sex and probe batch for gene expression levels) were made before analysis. To test the causal effect of 32 lead SNPs from the loci where annotated causal genes overlapped with MuTHER eQTLs, a Bonferronicorrected 99.85% confidence interval (~1 − 0.05/32) for the causal effect of gene expression levels on metabolite levels was obtained from 10,000 permutations, and the null hypothesis of no causation was rejected if the confidence interval did not cross zero ( Supplementary Table 11 ).
Drug associations.
A list of drugs approved by the FDA and/or the EMA was retrieved from the ChEMBL database. A total of 132 unique genes reported in npg
